Education
About Us
Working with TipRanks
Follow Us
Inmune Bio (INMB)
:INMB
INMB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.89 - $11.64
Previous CloseN/A
Volume114.20K
Average Volume (3M)6.21M
Market Cap
$71.51M
Enterprise Value$156.71M
Total Cash (Recent Filing)$19.34M
Total Debt (Recent Filing)$347.00K
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 07, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding26,585,258
10 Day Avg. Volume4,769,517
30 Day Avg. Volume6,209,768
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.19
Enterprise Value/Revenue3.13K
Enterprise Value/Gross Profit3.13K
Enterprise Value/Ebitda-3.77
Forecast
1Y Price Target
$7.72Price Target Upside169.93% Upside
Rating ConsensusHold
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial StabilityRecent equity financing raised $19 million, providing sufficient cash runway for the next 15-18 months, which is crucial for ongoing and future projects.
Market OpportunityWith the potential for premium pricing, this could represent a $1B opportunity.
Regulatory SupportThe FDA has indicated during a Type C meeting that the data from the study could support a filing.
Bears Say
Clinical Trial ChallengesThe Phase 2 MINDFuL study in Alzheimer's disease for XPro missed the primary endpoint for cognitive change, leading to a significant drop in INMB shares.
Development RisksThe timeline for the Alzheimer's program has been extended to 2033, with increased revenue risk adjustment, reflecting challenges in the development process.
Efficacy ConcernsThe Phase 2 study showed an effect size only in a subset of patients with greater neuroinflammation, suggesting limited broader efficacy.
Inmune Bio News
INMB FAQ
What was Inmune Bio’s price range in the past 12 months?
Inmune Bio lowest stock price was $1.89 and its highest was $11.64 in the past 12 months.
What is Inmune Bio’s market cap?
Inmune Bio’s market cap is $71.51M.
When is Inmune Bio’s upcoming earnings report date?
Inmune Bio’s upcoming earnings report date is Aug 07, 2025 which is today.
How were Inmune Bio’s earnings last quarter?
Inmune Bio released its earnings results on May 08, 2025. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.471 by $0.041.
Is Inmune Bio overvalued?
According to Wall Street analysts Inmune Bio’s price is currently Undervalued.
Does Inmune Bio pay dividends?
Inmune Bio does not currently pay dividends.
What is Inmune Bio’s EPS estimate?
Inmune Bio’s EPS estimate is -0.38.
How many shares outstanding does Inmune Bio have?
Inmune Bio has 26,585,258 shares outstanding.
What happened to Inmune Bio’s price movement after its last earnings report?
Inmune Bio reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.693%.
Which hedge fund is a major shareholder of Inmune Bio?
Currently, no hedge funds are holding shares in INMB
Inmune Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.72 (169.93% Upside)
$7.72 (169.93% Upside)
Blogger Sentiment
Bullish
INMB Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.79%
12-Months-Change
Fundamentals
Return on Equity
-139.01%
Trailing 12-Months
Asset Growth
-19.29%
Trailing 12-Months
Company Description
Inmune Bio
Inmune Bio, Inc. (INMB) is a biotechnology company focused on developing innovative therapies to modulate components of the immune system to treat cancer and neurodegenerative diseases. The company operates within the biotechnology and pharmaceutical sectors, leveraging its proprietary platforms to target innate immune cells. Core products in its pipeline include INKmune, which aims to enhance the ability of natural killer cells to attack cancer, and XPro1595, designed to inhibit neuroinflammation linked to Alzheimer's disease.
INMB Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights several promising developments, including increased market potential and positive safety data for XPro, progress in the INKmune program, and regulatory advancements for CORDstrom. However, these are tempered by financial constraints with a limited cash runway and delays in the U.S. IND for CORDstrom. While the company is optimistic about upcoming milestones, financial sustainability remains a concern.View all INMB earnings summariesINMB Stock 12 Month Forecast
Average Price Target
$7.72
▲(169.93% Upside)
Technical Analysis
Genfit SA
―
Annexon Biosciences
―
Innate Pharma
―
Design Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
17.01% Insiders
4.56% Mutual Funds
0.61% Other Institutional Investors
72.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---